Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.40 |
| ▸ | BACE1 | P56817 | 12/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CTSD | P07339 | 2/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401547 | 1.00 | MAPT (0.42) | MAPTNPY5RBACE1SLC6A4CTSD | |
| SCHEMBL4399028 | 0.88 | KDM4E (0.50) | BACE1CTSDBACE2 | |
| SCHEMBL4399031 | 0.88 | KDM4E (0.50) | BACE1CTSDBACE2 | |
| SCHEMBL4400890 | 0.83 | BACE1 (0.57) | BACE1CTSDBACE2 | |
| SCHEMBL4400888 | 0.83 | BACE1 (0.57) | BACE1CTSDBACE2 | |
| SCHEMBL4389966 | 0.83 | BACE1 (0.57) | BACE1CTSDBACE2 | |
| SCHEMBL4400657 | 0.83 | BACE1 (0.41) | BACE1CTSDLMNABACE2 | |
| SCHEMBL4394658 | 0.83 | BACE1 (0.57) | BACE1CTSDBACE2 | |
| SCHEMBL4393781 | 0.83 | BACE1 (0.41) | BACE1CTSDLMNABACE2 | |
| SCHEMBL3490766 | 0.83 | BACE1 (0.40) | MAPTBACE1CTSDLMNABACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1409450-B1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARM INC (US) | 2009-12-09 | — | — | EP | claimed |
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | PHARMACIA & UPJOHN COMPANY | 2003-06-12 | — | — | US | claimed |
| EP-1409450-B1 | N-(3-AMINO-2-HYDROXY-PROPYL) SUBSTITUTED ALKYLAMIDE COMPOUNDS | ELAN PHARM INC (US) | 2009-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109559-A1 | N-(3-amino-2-hydroxy-propyl)substituted alkylamide compounds | BACE1, APP, BACE2 | MAPT 204/4885NPY5R 1088/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.